Cervical Cancer Screening Portfolio

Evolving methods, one goal: the prevention of cervical cancer

most frequent
cancer in women1
women diagnosed/year1
women diagnosed/year1
While preventable, cervical cancer takes a heavy toll.
The high mortality rate from cervical cancer globally could be reduced through a comprehensive
approach that includes prevention, early diagnosis, effective screening and treatment programmes1

BD offers assays and instruments to support the cervical cancer
screening needs of today and tomorrow

The added complexity due to the HPV vaccination, in conjunction with the variability of screening methods, underscores the importance of a medical technology partner fully able to support and adapt to the requirements of healthcare providers and laboratories
BD offers assays

Cytology primary with ASCUS reflex

The BD SurePath™ Liquid-based Pap Test provides:

  • An FDA and CE-marked solution for primary cytology screening
  • Higher HSIL+ detection and lower unsatisfactory rate compared to conventional cytology and the ThinPrep® Pap Test2
  • 100% of collected sample sent to the laboratory for testing

The BD Onclarity™ HPV Assay provides:

  • An HPV solution for ASCUS reflex

HPV Primary

The BD Onclarity™ HPV Assay provides:

  • DNA-based PCR assay with proven and validated performance3
  • Internal cellularity control to minimize false-negative results
  • Enhanced genotyping to allow risk stratification and reduce unnecessary colposcopies
  • A CE-marked solution for self-collected vaginal specimens, to potentially extend cervical screening coverage by increasing participation rates3,4

The BD SurePath™ Liquid-based Pap Test provides:

  • An FDA and CE-marked collection vial for HPV primary screening
  • A cytology solution for reflex testing of HPV positive cases


The BD SurePath™ Collection Vial provides an FDA and CE-marked single source vial for cytology and HPV co-testing with the BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay

1. World Health Organization. Cervical cancer overview. Available at: Accessed September 2019.
2. Nance KV. Diagn Cytopathol. 2007; 35:148-153.
3. BD OnclarityTM HPV Assay EU Package Insert (8089899).
4. Saville M et al. J Clin Virol. 2020;127:104375.

Contact us

to discuss how we can support your cervical cancer
screening needs